Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target - Wikidata - wikimedia - TriplyDB

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

http://www.wikidata.org/entity/Q24559442

about

B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints Contemporary Treatment of Metastatic Renal Cell Carcinoma Cancer immunotherapy: the beginning of the end of cancer?PD-1/PD-L1 blockade in cancer treatment: perspectives and issues Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis A Perspective of Immunotherapy for Breast Cancer: Lessons Learned and Forward Directions for All Cancers Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations Nivolumab in the treatment of malignant melanoma: review of the literature Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence Immunotherapy for primary brain tumors: no longer a matter of privilege The blockade of immune checkpoints in cancer immunotherapy The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation Nivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers A fiber-modified adenoviral vector interacts with immunoevasion molecules of the B7 family at the surface of murine leukemia cells derived from dormant tumors Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape PD-L1 regulates the development, maintenance, and function of induced regulatory T cells PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome.Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma.FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy.In vitro and in vivo antivirus activity of an anti-programmed death-ligand 1 (PD-L1) rat-bovine chimeric antibody against bovine leukemia virus infection.Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy.Obesity is associated with a higher risk of clear-cell renal cell carcinoma than with other histologies.PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.Prognostic value of programmed death-ligand 1 expression in patients with stage III colorectal cancer B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis.Inhibitors of B7-CD28 costimulation in urologic malignancies.Programmed cell death ligand 1 expression in osteosarcoma.Novel immunotherapy in metastatic renal cell carcinoma.Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment

P2860

Q24550945-B360FF53-228A-4ED4-BCD5-FDA26236C653 Q24685406-181A89A5-D24A-494B-B3C3-5D175564BF06 Q26738729-0B44DAD1-546D-4298-9545-2DF1C25CBF43 Q26740594-01EF738B-2459-4D5A-A6DC-8237F7FADB2B Q26752277-31DAEE61-8D44-4A51-8D30-DCE6BFA06952 Q26768641-6EDE9B76-5899-4AB5-9E91-28DC7E9FCA56 Q26769728-1E307975-E547-4FA4-97FC-0846DA465C91 Q26775460-437AA2B9-9FD4-437A-BA3A-E6900E74D0C0 Q26777111-ED4AEC09-60BF-4981-A366-CF0982A00F98 Q26781038-F5D44D07-0910-4DF5-9DBA-DA85ABBFBD9F Q26798330-05DFA8AF-4850-457B-8FC6-FD33E07D180E Q26798402-2E46E4AC-8E13-4713-9E4B-0EC375AA2B8E Q26852704-0E081C4A-8FBF-49A3-A84C-39B84A61B9BC Q26865789-D0CBBCC7-7DA6-4E98-A501-2CBC50DB82F2 Q27002510-7363DD48-1A54-4980-9FC9-1EDEF12500B6 Q27860852-76EA0BD6-8AF6-471F-B0F4-19984E071332 Q28066941-FA13F3AB-9066-492A-A20E-A3194CB34C44 Q28068959-79A2EBC7-8A8D-4DF1-B6C7-6AAC5EFB7451 Q28075712-7A9266B5-7B79-438A-8597-C1B373E46B25 Q28084942-511CD27C-9282-4DEF-9B11-0407C39B299E Q28088496-AAC1104B-2374-4CB7-A81A-F756E86846C7 Q28306431-2F1335DA-A9F5-4164-AB43-440008BB300B Q28510246-CF2D8B33-A19B-4C52-B3BA-69E4430AD164 Q29620812-22B86AD4-48A7-4FB8-AC8F-AD65D8DC5AD0 Q29620881-6C95C950-1CB3-4779-98BD-043539C061E5 Q30080038-E612A80A-CECD-4066-A368-259A8EE9ECD2 Q30275174-B2A332D4-19CD-488A-A835-288198D230B0 Q33275611-05608513-5A5D-4701-A201-83831A1211EF Q33320890-E3C927D5-3ED3-4C72-A01B-33A6357F44DB Q33605673-B13512C5-461F-4749-A77B-13E1725B6AA4 Q33606111-5FCA4150-A6FB-4C46-B3E1-225A25491657 Q33636256-428B197D-7751-410B-9154-B869EED6EF9A Q33704636-90BEBA06-D27C-481E-9A51-294A31988CD7 Q33732329-F88309EC-D13E-48E2-AEB5-02A07A8A426E Q33738756-B2B2BED4-AD64-4416-BC98-D0E8A0645C6B Q33759287-923E8E4F-ED88-46DD-A424-171821F3E60D Q33827752-A710B4D3-5450-49CA-839F-644741E95F3A Q33848154-3432B53E-D278-4D6D-97F2-279F15D4F07F Q33863074-E88141B3-67A9-46B6-AC2B-8C057808F2C1 Q33894390-BE81880B-1E6E-4DDA-BD8D-05649A35F1C9

P2860

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

http://www.wikidata.org/entity/Q24559442

description

2004 nî lūn-bûn

@nan

2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Costimulatory B7-H1 in renal c ...... d potential therapeutic target

@ast

Costimulatory B7-H1 in renal c ...... d potential therapeutic target

@en

Costimulatory B7-H1 in renal c ...... d potential therapeutic target

@nl

type

label

Costimulatory B7-H1 in renal c ...... d potential therapeutic target

@ast

Costimulatory B7-H1 in renal c ...... d potential therapeutic target

@en

Costimulatory B7-H1 in renal c ...... d potential therapeutic target

@nl

prefLabel

Costimulatory B7-H1 in renal c ...... d potential therapeutic target

@ast

Costimulatory B7-H1 in renal c ...... d potential therapeutic target

@en

Costimulatory B7-H1 in renal c ...... d potential therapeutic target

@nl

P1433

Q24559442-F8EEAF5B-8F39-484B-A165-1D96EDF5EDA0

P1476

Q24559442-17B0E4E9-1046-4585-A091-D1B715CD647C

P2093

Q24559442-0EBED392-036B-48DB-9BA7-0FFC2440210A

Q24559442-14EBCAC0-5EB7-458A-9EE4-B9091ECA879B

Q24559442-19DF22E2-6D53-4546-A55C-9A80CFEAB815

Q24559442-19E9DE00-0122-46F7-BD0A-3BEDDDD13C4D

Q24559442-27D206B9-6E79-4AA8-94A1-9E5DD039A7F5

Q24559442-39C0E194-234C-4FE8-A1EE-4C026A7CB857

Q24559442-4B902CB2-F608-4B33-A75A-6B47BD0680F5

Q24559442-96ECE0EB-1B7D-44F6-AD3E-83C236E3E4A3

Q24559442-9EE0758C-0EE8-4B9B-B328-C41A64E14A95

Q24559442-B1BA66E5-CADD-4432-B561-FAA210BC17CD

P2860

Q24559442-00E4B66D-3991-4574-8401-0EB63C4EA852

Q24559442-0127F3CA-9F22-42B5-B2A2-E60D5692832E

Q24559442-0516C47F-A26C-4529-B2E5-0D1ACE094AB3

Q24559442-07A1B3AA-583C-458D-9533-4DA9E5EEE19E

Q24559442-140325AB-7CFF-47AE-97D2-E6A35ECD2976

Q24559442-1454F9FC-1398-4A6C-8E57-48A5A3A34AF6

Q24559442-1EDFAE78-08BB-4D13-A5D2-9683EDA68477

Q24559442-1F809FB4-B518-4B05-A645-F02AE8450C17

Q24559442-22E3B192-2024-46DD-8BA3-42E8EC4C09D7

Q24559442-322E590E-289D-4BB8-A088-E0EAE7764C85

P304

Q24559442-CDDDE853-3E35-4472-867F-80D7F23656F5

P31

Q24559442-BD70847B-7040-4FD0-9A81-5EC019E421E8

P3181

Q24559442-BFC12FF5-FF01-440C-A51F-CA67A2FFC9E4

P356

Q24559442-29FD6F3F-9835-40C7-9C69-AEFE268034D7

P407

Q24559442-62D98C4C-58C4-44B5-BB29-1F64DA7A3807

P433

Q24559442-3A7BCE7D-8E32-488A-B81A-D0D97C40D3A8

P478

Q24559442-6AAE5498-D81C-42AC-AE97-616E92D8FD76

P50

Q24559442-0D5C6895-7240-4154-A00E-2E09878E9F26

Q24559442-75F1568F-C7E8-4A67-94C4-1806A7C9ACEE

P577

Q24559442-F6791670-923A-4C52-B1CA-60E291E8CB35

P5875

Q24559442-F3BF761F-3AB9-4BA4-8EA7-C70F8A62F9E9

P698

Q24559442-531CAC50-010A-40CB-AE6E-99D4849533FD

P921

Q24559442-F818FF8A-507C-4535-A906-4A759920681F

P932

Q24559442-76D6366E-1640-499B-A3AC-298379F2AE8E

P3181

P356

PNAS.0406351101

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Costimulatory B7-H1 in renal c ...... d potential therapeutic target

@en

P2093

Bradley C Leibovich

http://www.w3.org/2001/XMLSchema#string

Christine M Lohse

http://www.w3.org/2001/XMLSchema#string

Eugene D Kwon

http://www.w3.org/2001/XMLSchema#string

Horst Zincke

http://www.w3.org/2001/XMLSchema#string

John C Cheville

http://www.w3.org/2001/XMLSchema#string

John R Lobo

http://www.w3.org/2001/XMLSchema#string

Kent G Krejci

http://www.w3.org/2001/XMLSchema#string

Lieping Chen

http://www.w3.org/2001/XMLSchema#string

Michael D Gillett

http://www.w3.org/2001/XMLSchema#string

Michael L Blute

http://www.w3.org/2001/XMLSchema#string

P2860

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy

PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells

The changing natural history of renal cell carcinoma.

Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma.

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

CTLA-4: new insights into its biological function and use in tumor immunotherapy.

P304

17174-17179

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

886333

http://www.w3.org/2001/XMLSchema#string

P356

10.1073/PNAS.0406351101

http://www.w3.org/2001/XMLSchema#string

P407

P433

49

http://www.w3.org/2001/XMLSchema#string

P478

101

http://www.w3.org/2001/XMLSchema#string

P50

Shomik Sengupta

Haidong D. Dong

P577

2004-11-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8157518

http://www.w3.org/2001/XMLSchema#string

P698

15569934

http://www.w3.org/2001/XMLSchema#string

P921

P932

534606

http://www.w3.org/2001/XMLSchema#string